Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

  • Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
  • Bavencio® (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
  • Braftovi® (encorafinib) + Mektovi® (binimetinib)​: BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
  • Duchenne Muscular Dystrophy Gene Therapy
  • fidanacogene elaparvovec (Coagulation Factor IX Gene Therapy): Hemophilia
  • giroctocogene fitelparvovec: Hemophilia Gene Therapy
  • Ibrance® (palbociclib): High Risk Early Breast Cancer, Early Breast Cancer in Adjuvant Setting, HER2+ Breast Cancer
  • Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
  • Prophylactic Vaccine: Clostridioides difficile Infection
  • Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata, Vitiligo
  • Talzenna® (talazoparib): Prostate Cancer
  • Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
  • Xeljanz® (tofacitinib): Ankylosing Spondylitis
  • Xtandi® (enzalutamide): Metastatic Hormone Sensitive Prostate Cancer, Non-Metastatic High Risk Hormone Sensitive Prostate Cancer

Pipeline Snapshot as of April 28, 2020

  • Discovery Projects
  • Phase 1
    27
  • Phase 2
    37
  • Phase 3
    21
  • Registration
    6
  • Total91
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
PF-06425090
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
Biopharma
Mechanism of Action:
Prophylactic Vaccine
Primary clostridioides difficile infection (FAST TRACK) Phase 3 New Molecular Entity Vaccine
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
Biopharma
Mechanism of Action:
Prophylactic Vaccine
Invasive and Non-Invasive Pneumococcal infections (Adult) (BREAKTHROUGH) Phase 3 New Molecular Entity Vaccine
PF-06760805
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Invasive Group B Streptococcus Infection (maternal) Phase 2 New Molecular Entity Vaccine
PF-06842433
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Invasive and Non-Invasive Pneumococcal infections (infants and children) Phase 2 New Molecular Entity Vaccine
PF-06886992
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Serogroups ABCWY Meningococcal Infections (adolescent and young adults) Phase 2 New Molecular Entity Vaccine
PF-06928316
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Respiratory Syncytial Virus Infection (maternal) Phase 2 New Molecular Entity Vaccine
PF-07302048 (BNT162)
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic mRNA Vaccine
COVID-19 Infection (in partnership with BioNTech)
Project advanced
Phase 1 New Molecular Entity Vaccine
Braftovi (encorafinib) + Erbitux®(cetuximab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
BRAF kinased inhibitor
2nd or 3rd Line BRAF-mutant Metastatic Colorectal Cancer (E.U.) Registration Product Enhancement Small Molecule
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Combo w/low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.) Registration New Molecular Entity Small Molecule
PF-06881894, a potential biosimilar to Neulasta® (Pegfilgrastim)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biosimilar
Business Segment:
Biopharma
Mechanism of Action:
Human Granulocyte Colony Stimulating Factor
Neutropenia in patients undergoing cancer chemotherapy (Biosimilar) (U.S., E.U.) Registration Biosimilar Biosimilar
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Androgen receptor inhibitor
Metastatic Hormone Sensitive Prostate Cancer (E.U.) Registration Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
1st Line Urothelial Cancer (Biologic) (BREAKTHROUGH - U.S)
Project advanced
Registration Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
1st Line Urothelial Cancer (Biologic) Phase 3 Product Enhancement Biologic
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Combo w/azacytidine in Acute Myeloid Leukemia (ORPHAN - U.S., E.U.) Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
High Risk Early Breast Cancer Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Early Breast Cancer in Adjuvant Setting Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
ER+/HER2+ Breast Cancer Phase 3 Product Enhancement Small Molecule